Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer

Michael Gorin, James E. Verdone, Emma van der Toom, Trinity Bivalacqua, Mohamad E Allaf, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer. Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide. CTCs have also been studied as predictive biomarkers of bladder cancer, in particular as a means to identify patients whose disease has been clinically understaged. Less is known regarding CTCs in kidney cancer; this has been attributed to the fact that a minority of renal tumours express EpCAM, the epithelial cell surface protein commonly used by CTC assays for positive cell selection. However, alternative approaches using markers specific for kidney cancer are being explored.

Original languageEnglish (US)
JournalNature Reviews Urology
DOIs
StateAccepted/In press - Nov 22 2016

Fingerprint

Circulating Neoplastic Cells
Kidney Neoplasms
Urinary Bladder Neoplasms
Prostatic Neoplasms
Biomarkers
Neoplasms
Castration
Androgens
Early Diagnosis
Membrane Proteins
Epithelial Cells
Kidney
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

@article{d661085a74264ed6b3ece9118ffddfeb,
title = "Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer",
abstract = "Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer. Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide. CTCs have also been studied as predictive biomarkers of bladder cancer, in particular as a means to identify patients whose disease has been clinically understaged. Less is known regarding CTCs in kidney cancer; this has been attributed to the fact that a minority of renal tumours express EpCAM, the epithelial cell surface protein commonly used by CTC assays for positive cell selection. However, alternative approaches using markers specific for kidney cancer are being explored.",
author = "Michael Gorin and Verdone, {James E.} and {van der Toom}, Emma and Trinity Bivalacqua and Allaf, {Mohamad E} and Kenneth Pienta",
year = "2016",
month = "11",
day = "22",
doi = "10.1038/nrurol.2016.224",
language = "English (US)",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer

AU - Gorin, Michael

AU - Verdone, James E.

AU - van der Toom, Emma

AU - Bivalacqua, Trinity

AU - Allaf, Mohamad E

AU - Pienta, Kenneth

PY - 2016/11/22

Y1 - 2016/11/22

N2 - Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer. Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide. CTCs have also been studied as predictive biomarkers of bladder cancer, in particular as a means to identify patients whose disease has been clinically understaged. Less is known regarding CTCs in kidney cancer; this has been attributed to the fact that a minority of renal tumours express EpCAM, the epithelial cell surface protein commonly used by CTC assays for positive cell selection. However, alternative approaches using markers specific for kidney cancer are being explored.

AB - Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer. Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide. CTCs have also been studied as predictive biomarkers of bladder cancer, in particular as a means to identify patients whose disease has been clinically understaged. Less is known regarding CTCs in kidney cancer; this has been attributed to the fact that a minority of renal tumours express EpCAM, the epithelial cell surface protein commonly used by CTC assays for positive cell selection. However, alternative approaches using markers specific for kidney cancer are being explored.

UR - http://www.scopus.com/inward/record.url?scp=84996940129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996940129&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2016.224

DO - 10.1038/nrurol.2016.224

M3 - Article

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

ER -